Litcius/Paper detail

Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers

Han Chen, Jessica L. Lawler, David J. Filman, James M. Hogle, Donald M. Coen

2021mBio11 citationsDOIOpen Access PDF

Abstract

While resistance to antiviral drugs can hinder their clinical use, understanding resistance mechanisms can illuminate how these drugs and their targets act. We studied a substitution in the human cytomegalovirus (HCMV) DNA polymerase that confers resistance to a leading anti-HCMV drug, ganciclovir. Ganciclovir is a nucleoside analog that terminates DNA replication after its triphosphate and the subsequent nucleotide are incorporated. We found that the substitution studied here results in an increased rate of extension of drug-containing DNA primers, thereby overcoming termination, which is a new mechanism of drug resistance. The substitution also induces more rapid extension of RNA primers, a function that had not previously been reported for HCMV polymerase. Thus, these results provide a novel resistance mechanism with potential implications for related nucleoside analogs that act against established and emerging viruses, and shed light on DNA polymerase functions.

Topics & Concepts

GanciclovirDrug resistanceDrugHuman cytomegalovirusNucleosideAntiviral drugVirologyNucleoside analoguePolymerasePharmacologyMedicineVirusDNABiologyMicrobiologyGeneticsCytomegalovirus and herpesvirus researchHIV Research and TreatmentHIV/AIDS drug development and treatment
Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers | Litcius